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Central nervous system (CNS) involvement in acute promyelocytic leukemia (APL) is rare, and the presence of CNS symptoms at 
the time of diagnosis of APL is even rarer. We report 2 cases of APL presenting with CNS involvement. A 43-yr-old woman present-
ed with easy bruising and stuporous mentality. Her complete blood count (CBC) revealed leukocytosis with increased blasts. Bone 
marrow (BM) analysis was carried out, and the diagnosis of APL was confirmed. This was done by cytogenetic analysis and demon-
stration of PML-RARα rearrangement by reverse transcriptase PCR in the BM cells. A lumbar puncture was performed to investigate 
the cause of her stuporous mentality, and her cerebrospinal fluid (CSF) analysis revealed 97% leukemic promyelocytes. Despite 
systemic and CNS therapy, she died due to septic shock by infection and rapid disease progression only 3 days after her admission. 
Another patient, a 3-yr-old girl, presented with easy bruising and epistaxis, and her CBC showed pancytopenia with increased 
blasts. BM studies confirmed APL. Quantitative PCR for PML-RARα in the BM cells revealed a PML-RARα/ABL ratio of 0.33 and CSF 
analysis revealed 9.5% leukemic promyelocytes (2 of 21 cells). She received induction chemotherapy and intrathecal therapy and 
achieved complete remission (CR) in the BM and CNS. She has been maintained in the CR status for the past 31 months. Thus, pa-
tients with APL must be evaluated for CNS involvement if any neurological symptoms are present at the time of diagnosis.
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INTRODUCTION
Central nervous system (CNS) involvement is a rare com-
plication of acute promyelocytic leukemia (APL) and is en-
countered more frequently at the relapse stage than at pre-
sentation. The CNS is the most commonly affected site of 
extramedullary relapse in APL [1, 2]. The incidence of CNS 
relapse ranges between 0.6% and 2% [2-4]. Furthermore, 
CNS involvement at the time of presentation is very rare, 
and only few cases have been reported in medical literature 
[5-9].
In this paper, we report 2 cases of APL with CNS involve-
ment at the time of disease presentation.
 
CASE REPORT
1. Case 1
A 43-yr-old woman presented with easy bruising for a 
month and stuporous mentality for several hours in Febru-
ary 2009. Initial laboratory evaluation showed a white blood 
cell (WBC) count of 48.6×10
9/L with 87% blasts, a hemo-
globin count of 31 g/L, and a platelet count of 14×10
9/L. 
Prothrombin time (PT) and activated partial thromboplastin 
time (aPTT) at the time of admission were 14.5 sec (59% of 
normal) and 28.3 sec, respectively. The findings of other co-
agulation tests were as follows: fibrinogen level, 1.14 g/L; fi-
brin/fibrinogen degradation product level, 546.8 mg/L; and 
D-dimer level, 283,600 μg/L. These indicated disseminated 
intravascular coagulation. Numerous hypergranular pro-
myelocytes (42%) and myeloblasts (41%) were visualized 
on bone marrow (BM) examination. Immunophenotyping 
of the BM revealed that leukemic cells were positive for 
CD13, CD33, CD117, and CD65 and negative for CD34, 10     www.kjlm.org
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CD15, and CD2. HLA-DR showed dim positivity. The chro-
mosomal analysis of BM cells showed the karyotype 46,XX, 
t(15;17)(q22;q21)[3]/46,XX,der(15)t(15;17)(q22;q21),ider 
(q10)(15;17) in 17 of the 20 metaphase cells. Reverse tran-
scriptase PCR (RT-PCR) showed a bcr1 isoform of the PML-
RARα fusion transcript in the BM specimen. For RT-PCR, 
total RNA was extracted from the BM cells using a High 
Pure RNA isolation kit (Roche Diagnostics, Mannheim, 
Germany), and reverse transcription was performed using 
Moloney murine leukemia virus transcriptase enzyme (In-
vitrogen, Carlsbad, CA, USA) and a hexanucleotide mix-
ture (Roche Diagnostics). Nested PCR was performed using 
GeneAmp PCR System 9600 (Perkin-Elmer, Norwalk, CT, 
USA) [10].
A brain CT scan did not show any tumor or CNS hemor-
rhage. A lumbar puncture was performed to investigate the 
cause of her stuporous mentality; and cerebrospinal fluid 
(CSF) analysis revealed a WBC count of 2.2×10
9/L, red 
blood cell (RBC) count of 0.16×10
12/L, and leukemic pro-
myelocyte proportion of 97% in the bloody background 
(Fig. 1). Cytospins were prepared from CSF cells using a 
Shandon Cytospin 3 (Shandon, Astmoore, UK). The load-
ing volume was 5 drops and centrifugation was performed 
at 700 rpm for 5 min. Next, Wright-Giemsa staining was 
carried out. The CSF specimen was not subjected to RT-
PCR or FISH analysis.
Induction chemotherapy with all-trans-retinoic acid (AT-
RA) and idarubicin was initiated and intrathecal metho-
trexate (20 mg) was administered simultaneously. However, 
the patient’s mentality and clinical condition worsened pro-
gressively and she died due to septic shock by infection and 
rapid disease progression only 3 days after admission.
2. Case 2
A 3-yr-old girl presented with easy bruising and epistaxis 
for several days in August 2007. Her initial laboratory eval-
uation revealed pancytopenia with a WBC count of 3.8× 
10
9/L and 8% blasts, hemoglobin level of 46 g/L, and a plate-
let count of 27×10
9/L. Coagulation test results were within 
the normal range. The BM finding of hypergranular promy-
elocytes was consistent with the diagnosis of APL. Immun-
ophenotyping of BM leukemic cells showed that they were 
positive for CD13, CD33, and CD117 and negative for CD34, 
HLA-DR, and CD2. The chromosomal analysis showed the 
karyotype 46,XX,t(15;17)(q22;q21) in 7 of 20 metaphase 
cells. RT-PCR of the BM specimen showed the bcr3 isoform 
of the PML-RARα fusion transcript and the ratio of PML-
RARα/ABL determined by with quantitative PCR was 0.33. 
The patient had no neurological symptoms. However, a lum-
bar puncture was done for the purpose of CNS prophylaxis. 
CSF analysis revealed 9.5% leukemic promyelocytes (2 of 
21 cells) with a WBC count of 0.002×10
9/L without RBCs. 
The CSF specimen was not subjected to RT-PCR or FISH 
analysis.
The patient received induction chemotherapy with ATRA, 
idarubicin, and cytarabine, and intrathecal cytarabine (40 
mg) as per the protocol. No leukemic cells were detected 
during the follow-up CSF examination. She achieved remis-
sion in the BM and CNS. She was then prescribed consoli-
dation and maintenance therapy with cytarabine and idaru-
bicin. At present she is alive and in a CR status for 31 months.
 
DISCUSSION
APL is a unique disease entity associated with distinctive 
morphology and chromosomal abnormality, and it is often 
accompanied by severe coagulopathy [11]. In these cases, 
performing a lumbar puncture at disease presentation or 
induction therapy is extremely hazardous because of fre-
quently encountered bleeding diathesis and therefore, not 
recommended in patients with newly diagnosed APL in 
general [12]. However, the presence of neurological symp-
toms such as headache, vertigo, nausea, vomiting, visual 
disturbance, seizure, and altered mental state [13, 14], ne-
cessitate a lumbar puncture both for diagnostic and thera-
peutic purposes [9, 12]. In our cases, the first patient pre-
sented with altered mentality, and the second patient had no 
neurological symptoms. However, in the hematology and 
oncology division of the pediatric department in our insti-
tution, all APL patients undergo prophylactic lumbar punc-
tures irrespective of their age or presence of neurological 
symptoms. Chow et al. recommended lumbar puncture at 
Fig. 1. Cytospin preparation of the cerebrospinal fluid of Case 1 showing pro-
myelocytes with Auer rods in the cytoplasm. Numerous red blood cells are 
seen in the background (Wright-Giemsa stain, ×1,000).Ji M, et al.  •  APL with CNS Involvement
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the time of APL diagnosis, immediately after the resolution 
of coagulopathy in order to diagnose CNS involvement [4].
In Case 2, the 3-yr-old girl was unable to express the dis-
ease-related symptoms accurately. In addition, CSF analysis, 
showed a smaller number of leukemic cells (2 of 21 cells, 
WBC count, 0.002×10
9/L) than that in Case 1 (leukemic 
promyelocytes, 97%; WBC 2.2×10
9/L).
There have been several reports of patients with APL pre-
senting with CNS involvement in APL at the time of initial 
diagnosis (Table 1). Two cases of APL with CNS involve-
ment have been reported in Korea [13, 15], and in both of 
these cases, CNS was affected during relapse: one showed 
CNS involvement with molecular relapse in the BM, and 
the second showed CNS involvement with hematologic re-
mission in the BM. To our knowledge, our report is the first 
to present cases of CNS involvement at the time of diagno-
sis of APL in Korea.
Treatment of CNS involvement in APL can be diverse 
and can also be case-specific. It includes local and systemic 
therapy. CNS therapy comprises of intrathecal chemother-
apy, for example, cytarabine, methotrexate and hydrocorti-
sone, and CNS irradiation, while systemic therapy involves 
the administration of ATRA in addition to chemotherapy 
[3, 14]. Both our patients received intrathecal methotrexate 
or cytarabine and systemic chemotherapy, including ATRA.
No molecular studies were performed with the CSF spec-
imen in either of the patients, because cytological examina-
tion of CSF was considered sufficient to diagnose CNS in-
volvement. However, this limited the comparison of our 
cases with a recently reported case [9], because we did not 
have data on the PML-RARα fusion transcript in the CSF 
leukemic cells.
In summary, we describe 2 cases of APL with CNS in-
volvement at the time of presentation. Although CNS in-
volvement is a very rare event in APL at the time of initial 
diagnosis, we believe that APL patients with neurological 
symptoms must be evaluated for CNS involvement by per-
forming a lumbar puncture.
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